Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PADN for Pulmonary Hypertension Associated With Left Heart Failure
NCT05824923Phase 3Active, not recruiting
- Sponsor
- Pulnovo Medical
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pulmonary hypertension (PH) and heart failure (HF) (2 arms), sponsored by Pulnovo Medical. Primary endpoint: Clinical Worsening at 6 months. Started Aug 2023; status: active, not recruiting.
02
Conditions
pulmonary hypertension (PH)heart failure (HF)
Beyond the preview
Go deeper on NCT05824923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05824923.